Elliot Cahn
YOU?
Author Swipe
View article: Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma
Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma Open
Introduction The LEO Comorbidity Index (LCI), comprising ten equally weighted comorbidity categories (respiratory, cardiovascular, digestive, hepatic, renal, autoimmune, diabetes, cancer history, HIV, and stroke), has demonstrated prognost…
View article: FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting
FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting Open
Background: Prognostication for patients with non-transformed relapsed/refractory (R/R) follicular lymphoma (FL) is not well defined. Progression of disease within 24 months (POD24) and number of lines of prior therapy are commonly used to…
View article: Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation Open
Introduction Short diagnosis-to-treatment interval (DTI) is associated with aggressive disease biology and inferior outcomes in diffuse large B-cell lymphoma (DLBCL), and is recognized as a potential source of selection bias in clinical tr…
View article: FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis Open
Introduction Marginal zone lymphoma (MZL) is an indolent and heterogenous disease. Several prognostic models have been proposed to assess outcomes in MZL, including FLIPI, IPI (primarily designed for overall survival [OS]), and MZL-specifi…
View article: Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Open
Background: The Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI, Zoref-Lorenz et al, Blood, 2022) index, defined by the combined elevation in serum soluble CD25 (sCD25) and ferritin, has emerged as a promising prognost…